Copaxone

Teva stock plummets by double figures on back of U.S. government kickback lawsuit

18.08.20 | CTech and Sophie Shulman

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19 | Uri Tal-Tene

Senior Teva R&D Executive Joins Cannabis Company Cannassure

18.08.19 | Tzally Greenberg

Credit Line and Bonds: Teva's Financial Catch

12.08.19 | Uri Tal-Tene

Former Execs, Directors, to Pay Teva $50 Million for Part in Bribery Damages

25.07.19 | Tomer Ganon

Where is Kåre Schultz?

17.07.19 | Sophie Shulman

Teva Makes Headway in European Copaxone Patent Case

01.04.19 | Lilach Baumer

Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant

19.03.19 | Lilach Baumer

Teva to Close 11 More Manufacturing Facilities in 2019

14.02.19 | Lilach Baumer

Teva Falls in Pre-Market Following Low-Profit Forecasts for 2019

13.02.19 | Lilach Baumer

Copaxone Profit will Continue to Fall, But Teva is Set to Double Down on Biosimilars

08.01.19 | Lilach Baumer and Hezi Sternlicht

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18 | Lilach Baumer

Teva Shut Down New York, Washington Offices, Says CEO

23.02.18 | Dror Reich

Teva Executive Calls Company’s Fourth Quarter “Fairly Good”

11.02.18 | Dror Reich

The Crucial Piece of Information Teva Overlooked

24.12.17 | Sophie Shulman

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17 | Uri Tal-Tenne

With New CEO in Seat, Teva Lowers Outlook

02.11.17 | Lilach Baumer and Dror Reich

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17 | Lilach Baumer

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17 | Lilach Baumer

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17 | Lilach Baumer

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17 | Lilach Baumer

Teva Loses Copaxone Market Exclusivity

04.10.17 | Lilach Baumer

New CEO to Break Teva’s Copaxone Habit

11.09.17 | Sophie Shulman, Dror Reich

With Bloated Debt, Teva Looks to Sell Assets

10.08.17 | Eli Shimony and Gil Kalian